Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 27Dermatologic 4Thoracic 3Gynecologic 3Breast 3Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2CNS 2Plasma cell 1Endocrine 1

Conditions

Lymphoma, Mantle-Cell 11Lymphoma, Non-Hodgkin 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Follicular 5Lymphoma 5Hodgkin Disease 5Waldenstrom Macroglobulinemia 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Neoplasms 3Recurrence 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Carcinoma, Renal Cell 2Burkitt Lymphoma 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasm Metastasis 1Mycosis Fungoides 1

Interventions

fludarabine phosphate 7pembrolizumab 6Mycophenolic Acid 6Peripheral Blood Stem Cell Transplantation 5Nivolumab 5Cyclosporine 5Cyclophosphamide 5Whole-Body Irradiation 4Radiotherapy 3Busulfan 3Antilymphocyte Serum 3temsirolimus 2fludarabine 2atezolizumab 2alectinib 2Tacrolimus 2Sunitinib 2Specimen Handling 2Paclitaxel 2Methotrexate 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Dasatinib 2Alemtuzumab 2varlilumab 1valspodar 1utomilumab 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × temsirolimus × Lymphoid × Clear all
NCT01367457 2016-04-27

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Pfizer

Completed
243 enrolled 12 charts
GenitourinaryLymphoid

Carcinoma, Renal Cell, Lymphoma, Mantle-Cell

NCT00659568 2013-05-30

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
28 enrolled
BreastDermatologicGenitourinaryGynecologicLymphoidOther hematologic neoplasmThoracic

Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Renal Cell, Hodgkin Disease, Immunoblastic Lymphadenopathy, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Endometrial Neoplasms, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡